Seminars in Oncology Nursing
Volume 25, Issue 3 , Pages 193-202 , August 2009

Radiation Therapy for Head and Neck Cancers

  • Indranil Mallick
    • ,
  • John N. Waldron

      Affiliations

    • Corresponding Author InformationAddress correspondence to John N. Waldron, MSc, MD, FRCPC, Department of Radiation Oncology, Princess Margaret Hospital, 610 University Ave., Toronto, ON, Canada M5G 2M9

References 

  1. Lee N, Xia P, Quivey JM, et al. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys. 2002;53:12–22
  2. Kam MK, Leung SF, Zee B, et al. Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. J Clin Oncol. 2007;25:4873–4879
  3. Jabbari S, Kim HM, Feng M, et al. Matched case-control study of quality of life and xerostomia after intensity-modulated radiotherapy or standard radiotherapy for head-and-neck cancer: initial report. Int J Radiat Oncol Biol Phys. 2005;63:725–731
  4. Cannon DM, Lee NY. Recurrence in region of spared parotid gland after definitive intensity-modulated radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys. 2008;70:660–665
  5. Hall EJ. The inaugural Frank Ellis Lecture–Latrogenic cancer: the impact of intensity-modulated radiotherapy. Clin Oncol (R Coll Radiol). 2006;18:277–282
  6. Horiot JC, Le Fur R, N'Guyen T, et al. Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother Oncol. 1992;25:231–241
  7. Overgaard J, Hansen HS, Specht L, et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet. 2003;362:933–940
  8. Fu KK, Pajak TF, Trotti A, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys. 2000;48:7–16
  9. Dische S, Saunders M, Barrett A, et al. A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother Oncol. 1997;44:123–136
  10. Waldron J, Warde P, Irish J, et al. A dose escalation study of hyperfractionated accelerated radiation delivered with integrated neck surgery (HARDWINS) for the management of advanced head and neck cancer. Radiother Oncol. 2008;87:173–180
  11. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31:1341–1346
  12. Dische S, Saunders MI. The CHART regimen and morbidity. Acta Oncol. 1999;38:147–152
  13. Bourhis J, Overgaard J, Audry H, et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet. 2006;368:843–854
  14. Pignon JP, le Maitre A, Bourhis J. Meta-Analyses of Chemotherapy in Head and Neck Cancer (MACH-NC): an update. Int J Radiat Oncol Biol Phys. 2007;69:S112–S114
  15. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003;349:2091–2098
  16. Denis F, Garaud P, Bardet E, et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol. 2004;22:69–76
  17. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567–578
  18. Pedruzzi PA, Kowalski LP, Nishimoto IN, et al. Analysis of prognostic factors in patients with oropharyngeal squamous cell carcinoma treated with radiotherapy alone or in combination with systemic chemotherapy. Arch Otolaryngol Head Neck Surg. 2008;134:1196–1204
  19. Nguyen NP, North D, Smith HJ, et al. Safety and effectiveness of prophylactic gastrostomy tubes for head and neck cancer patients undergoing chemoradiation. Surg Oncol. 2006;15:199–203
  20. Wiggenraad RG, Flierman L, Goossens A, et al. Prophylactic gastrostomy placement and early tube feeding may limit loss of weight during chemoradiotherapy for advanced head and neck cancer, a preliminary study. Clin Otolaryngol. 2007;32:384–390
  21. Jham BC, Reis PM, Miranda EL, et al. Oral health status of 207 head and neck cancer patients before, during and after radiotherapy. Clin Oral Invest. 2008;12:19–24
  22. Nguyen NP, Frank C, Moltz CC, et al. Aspiration rate following chemoradiation for head and neck cancer: an underreported occurrence. Radiother Oncol. 2006;80:302–306
  23. Cawley MM, Benson LM. Current trends in managing oral mucositis. Clin J Oncol Nurs. 2005;9:584–592
  24. Harris DJ, Eilers J, Harriman A, et al. Putting evidence into practice: evidence-based interventions for the management of oral mucositis. Clin J Oncol Nurs. 2008;12:141–152
  25. Rubenstein EB, Peterson DE, Schubert M, et al. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer. 2004;100:2026–2046
  26. Quinn B, Potting CM, Stone R, et al. Guidelines for the assessment of oral mucositis in adult chemotherapy, radiotherapy and haematopoietic stem cell transplant patients. Eur J Cancer. 2008;44:61–72
  27. Keefe DM, Schubert MM, Elting LS, et al. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer. 2007;109:820–831
  28. Rosenthal DI, Trotti A. Strategies for managing radiation-induced mucositis in head and neck cancer. Semin Radiat Oncol. 2009;19:29–34
  29. Colasanto JM, Prasad P, Nash MA, et al. Nutritional support of patients undergoing radiation therapy for head and neck cancer. Oncology (Williston Park). 2005;19:371–379discussion 380-372, 387
  30. Rosenthal DI, Lewin JS, Eisbruch A. Prevention and treatment of dysphagia and aspiration after chemoradiation for head and neck cancer. J Clin Oncol. 2006;24:2636–2643
  31. Miller EH, Quinn AI. Dental considerations in the management of head and neck cancer patients. Otolaryngol Clin North Am. 2006;39:319–329
  32. Bolderston A, Lloyd NS, Wong RK, et al. The prevention and management of acute skin reactions related to radiation therapy: a systematic review and practice guideline. Support Care Cancer. 2006;14:802–817
  33. McQuestion M. Evidence-based skin care management in radiation therapy. Semin Oncol Nurs. 2006;22:163–173
  34. Eisbruch A, Ten Haken RK, Kim HM, et al. Dose, volume, and function relationships in parotid salivary glands following conformal and intensity-modulated irradiation of head and neck cancer. Int J Radiat Oncol Biol Phys. 1999;45:577–587
  35. Pow EH, Kwong DL, McMillan AS, et al. Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial. Int J Radiat Oncol Biol Phys. 2006;66:981–991
  36. Eisbruch A, Kim HM, Terrell JE, et al. Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2001;50:695–704
  37. Rudat V, Munter M, Rades D, et al. The effect of amifostine or IMRT to preserve the parotid function after radiotherapy of the head and neck region measured by quantitative salivary gland scintigraphy. Radiother Oncol. 2008;89:71–80
  38. Eisbruch A. Reducing xerostomia by IMRT: what may, and may not, be achieved. J Clin Oncol. 2007;25:4863–4864
  39. Ruo Redda MG, Allis S. Radiotherapy-induced taste impairment. Cancer Treat Rev. 2006;32:541–547
  40. Eisbruch A, Lyden T, Bradford CR, et al. Objective assessment of swallowing dysfunction and aspiration after radiation concurrent with chemotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2002;53:23–28
  41. Feng FY, Kim HM, Lyden TH, et al. Intensity-modulated radiotherapy of head and neck cancer aiming to reduce dysphagia: early dose-effect relationships for the swallowing structures. Int J Radiat Oncol Biol Phys. 2007;68:1289–1298
  42. Gillespie MB, Brodsky MB, Day TA, et al. Swallowing-related quality of life after head and neck cancer treatment. Laryngoscope. 2004;114:1362–1367
  43. Jereczek-Fossa BA, Orecchia R. Radiotherapy-induced mandibular bone complications. Cancer Treat Rev. 2002;28:65–74
  44. Pitak-Arnnop P, Sader R, Dhanuthai K, et al. Management of osteoradionecrosis of the jaws: an analysis of evidence. Eur J Surg Oncol. 2008;34:1123–1134
  45. Tell R, Sjodin H, Lundell G, et al. Hypothyroidism after external radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys. 1997;39:303–308
  46. Garcia-Serra A, Amdur RJ, Morris CG, et al. Thyroid function should be monitored following radiotherapy to the low neck. Am J Clin Oncol. 2005;28:255–258
  47. Abayomi OK. Pathogenesis of cognitive decline following therapeutic irradiation for head and neck tumors. Acta Oncol. 2002;41:346–351
  48. Yuen HK, Sharma AK, Logan WC, et al. Radiation dose, driving performance, and cognitive function in patients with head and neck cancer. Radiother Oncol. 2008;87:304–307
  49. Cheung M, Chan AS, Law SC, et al. Cognitive function of patients with nasopharyngeal carcinoma with and without temporal lobe radionecrosis. Arch Neurol. 2000;57:1347–1352

PII: S0749-2081(09)00061-8

doi: 10.1016/j.soncn.2009.05.002

Seminars in Oncology Nursing
Volume 25, Issue 3 , Pages 193-202 , August 2009

Article Tools